ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisFred Poordad, Barry Bernstein, Barbara Da Silva‐Tillmann et al.|New England Journal of Medicine|2014Cited by 877
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J. Sonneveld, Benjamin Maasoumy, Shao‐Ming Chiu et al.|Journal of Hepatology|2022Cited by 121
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J. Sonneveld, Benjamin Maasoumy, Jun Yong Park et al.|Clinical Gastroenterology and Hepatology|2020Cited by 103
A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis BAdrian Streinu‐Cercel, Patricia Méndez, Edward Gane et al.|Journal of Hepatology|2017Cited by 34
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J. Sonneveld, Benjamin Maasoumy, Shao‐Ming Chiu et al.|Gastroenterology|2023Cited by 23